| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1136/ARD.2008.091926 |
| P698 | PubMed publication ID | 18647854 |
| P50 | author | Deborah P.M. Symmons | Q54100237 |
| Lars Klareskog | Q5912759 | ||
| P2093 | author name string | A J Silman | |
| W G Dixon | |||
| A Zink | |||
| J Askling | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1240-1246 | |
| P577 | publication date | 2008-07-22 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | European biologicals registers: methodology, selected results and perspectives | |
| P478 | volume | 68 |
| Q43806587 | A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals |
| Q54469391 | A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan. |
| Q94595231 | Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort |
| Q34613898 | Applying science in practice: the optimization of biological therapy in rheumatoid arthritis |
| Q57244402 | Assessing and Explaining the Evidence on Harms of Medical Interventions |
| Q36934322 | Biologic agents in systemic vasculitis. |
| Q44030942 | Biosimilars : Current state of the build up to series production |
| Q34296816 | Challenges for synthesising data in a network of registries for systemic psoriasis therapies |
| Q90260122 | Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR |
| Q84587921 | Comparative effectiveness of rheumatoid arthritis therapies |
| Q38217664 | Comparison of characteristics of international and national databases for rheumatoid arthritis: a systematic literature review |
| Q42972407 | Considering comorbidity in managing rheumatic diseases: going where trials cannot go. |
| Q41601731 | Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies |
| Q34582779 | Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules |
| Q28650413 | Dynamic consent: a possible solution to improve patient confidence and trust in how electronic patient records are used in medical research |
| Q35620336 | Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors |
| Q34238357 | Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity |
| Q56969640 | Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries |
| Q45970934 | Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. |
| Q56969682 | Looking beyond incidence in the relationship between anti-tumor necrosis factor therapy and malignancy |
| Q38533964 | Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden |
| Q33829777 | Quality and completeness of utilisation data on biological agents across European countries: tumour necrosis factor alpha inhibitors as a case study |
| Q40000074 | Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan |
| Q33731716 | Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis |
| Q26991673 | Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies |
| Q38176745 | Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis |
| Q93064067 | Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study |
| Q40807740 | Serious infections in patients with rheumatoid arthritis |
| Q33998050 | Summary of worldwide pediatric malignancies reported after exposure to etanercept |
| Q29395899 | The Value of Patient-Centred Registries in Phase IV Drug Surveillance |
| Q34164644 | The immune system in atherosclerosis |
| Q37974121 | The practical value of biologics registries in Africa and Middle East: challenges and opportunities |
| Q38063474 | The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment |
| Q37715703 | The safety and side effects of monoclonal antibodies |
| Q38173669 | The safety of biologic therapies in RA-associated interstitial lung disease |
| Q38264987 | Traceability of biologicals: present challenges in pharmacovigilance |
| Q35249608 | Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? |
| Q34249182 | Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry |
| Q34620375 | Update of the management of chronic psoriasis: new approaches and emerging treatment options. |
| Q84602740 | Update on Biologic Therapy in the Management of Axial Spondyloarthritis |
| Q47120472 | Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment |
| Q33694218 | Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study |
| Q37347648 | Validity of physician-reported hospitalized infections in a US arthritis registry |
Search more.